@EU_Startups
via X
#Basel-based #Nouscom, a clinical-stage, #cancer interception focused #BioTech developing next-gen immunotherapies, has raised €120 million in #SeriesD for cancer immunotherapy 🇨🇭🧬

https://t.co/vcFImHFuEx

Cookies allow you to use this website normally and customize your experience on this website.

>>More information